TABLE 4.

Linear regression with change in acute medication, triptans, pain coping and general well‐being at 3 months in patients switching to a second CGRP‐mAb (n = 31) and controls (n = 36).

	Switchers (n = 31)	Controls (n = 36)	Difference (95% CI) a	p value*
∆ Acute medication days, mean ± SD	−1.2 (2.7)	−0.03 (2.6)	−0.4 (−1.6, 2.8)	0.48
∆ Triptan days, mean ± SD	−0.94 (2.05)	0.06 (2.06)	−0.4 (−1.3, 0.6)	0.46
∆ Pain coping b , mean ± SD	0.24 (0.74)	−0.22 (0.75)	0.5 (0.05, 0.85)	0.03
∆ General well‐being c , median ± IQR	0.5 (4.5)	−1.7 (3.5)	2.3 (0.5, 4.9)	0.01

Abbreviations: CGRP‐mAb, anti‐calcitonin gene‐related peptide monoclonal antibody; CI, confidence interval; IQR, interquartile range.

^a Difference in least‐squares mean from control group.

^b Scored on a 0–10 visual analogue scale, with 0,very bad; 10, very good.

^c Scored on a 0–100 visual analogue scale, with 0, very bad; 100, very good.

^* p values are for the control group versus switcher group. p‐value < 0.05 was considered statistically significant.